Investor Relations

Latest News

September 30, 2022 9:59am EDT

Todos Medical Receives Two Notices of Allowance from USPTO for AI-Based TBIA Pan-Cancer Blood Diagnostics Platform

September 27, 2022 12:02pm EDT

Todos Medical Announces USPTO Trademark Notice of Allowance for 3CL Protease Biomarker Diagnostics TolloTest™

September 22, 2022 4:02pm EDT

Todos Medical Enters Into $50M Contract to Supply Tollovid™ and CBD Products to Retail Distributor Company Nerd Hemp

September 16, 2022 7:30am EDT

Todos Medical Announces NFL Hall of Famer Michael Irvin as Tollovid™ Sports Ambassador for #TolloUp Campaign

View all news

Latest Presentation

Mar 1, 2022

Corporate Presentation

View Presentation

Recent Event

Sep 28, 2022 9:00 am EDT

Annual General Meeting of Shareholders

View All Events

Latest Financial Results

Q2 2022

Quarter Ended June 30, 2022

Earnings Release

PDF HTML

Audio

Earnings Webcast

10-Q

PDF HTML

XBRL

ZIP XLS HTML

Latest Annual Filing

For Fiscal Year Ending December 31, 2021

Company Overview

Todos Medical Ltd. is an in-vitro diagnostic company engaged in the development of blood tests for the early detection of a variety of cancers, and also has initiated the development of blood tests for neurodegenerative disorders such as Alzheimer's disease through Breakthrough Diagnostics, Inc., its joint venture with Amarantus Bioscience Holdings, Inc. Todos has developed two cancer screening tests based on TBIA (Todos Biochemical Infrared Analyses), a method for cancer screening using peripheral blood analysis. The TBIA screening method is based on the cancer’s influence on the immune system, which triggers biochemical changes in peripheral blood mononuclear cells and plasma. This proprietary and patented method incorporates biochemistry, physics and signal processing. The company’s two cancer screening tests, TM-B1 and TM-B2, have received the CE mark. Todos owns 19.99% of Breakthrough Diagnostics, Inc., a joint venture with Amarantus Bioscience Holdings, Inc. (OTCPK:AMBS) that is developing the LymPro Test®, a blood test for diagnosing Alzheimer’s disease. Todos has exercised its option to acquire Breakthrough, and expects to close on that transaction in the first half of 2020. Todos has also entered into an exclusive option to acquire breast cancer blood testing company Provista Diagnostics, Inc. that is commercializing the Videssa® breast cancer blood test.

View Management Team View Board of Directors

IR Contacts

Company

Todos Medical Ltd.
121 Derech Menachem Begin, 30th Floor
Tel Aviv 6701203
Israel
T: +972-73-207-7259

Todos Medical U.S.A.
40 Wall Street, Suite 2702
New York, NY 10005
T: +1-917-983-4229